248 related articles for article (PubMed ID: 29032274)
1. Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.
Hill BT; Ahn KW; Hu ZH; Aljurf M; Beitinjaneh A; Cahn JY; Cerny J; Kharfan-Dabaja MA; Ganguly S; Ghosh N; Grunwald MR; Inamoto Y; Kindwall-Keller T; Nishihori T; Olsson RF; Saad A; Seftel M; Seo S; Szer J; Tallman M; Ustun C; Wiernik PH; Maziarz RT; Kalaycio M; Alyea E; Popat U; Sobecks R; Saber W
Biol Blood Marrow Transplant; 2018 Mar; 24(3):581-586. PubMed ID: 29032274
[TBL] [Abstract][Full Text] [Related]
2. Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis.
William BM; Wang T; Haagenson MD; Fleischhauer K; Verneris M; Hsu KC; de Lima MJ; Fernandez-Viña M; Spellman SR; Lee SJ; Hill BT
Biol Blood Marrow Transplant; 2018 Apr; 24(4):827-831. PubMed ID: 29155319
[TBL] [Abstract][Full Text] [Related]
3. Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada.
Huang SJ; Chan J; Bruyère H; Allan LL; Gerrie AS; Toze CL
Leuk Res; 2019 Sep; 84():106193. PubMed ID: 31325731
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens.
Kharfan-Dabaja MA; Bazarbachi A
Cancer Control; 2012 Jan; 19(1):68-75. PubMed ID: 22143063
[TBL] [Abstract][Full Text] [Related]
6. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.
Kharfan-Dabaja MA; Kumar A; Hamadani M; Stilgenbauer S; Ghia P; Anasetti C; Dreger P; Montserrat E; Perales MA; Alyea EP; Awan FT; Ayala E; Barrientos JC; Brown JR; Castro JE; Furman RR; Gribben J; Hill BT; Mohty M; Moreno C; O'Brien S; Pavletic SZ; Pinilla-Ibarz J; Reddy NM; Sorror M; Bredeson C; Carpenter P; Savani BN
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2117-2125. PubMed ID: 27660167
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
[TBL] [Abstract][Full Text] [Related]
8. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Chavez JC; Kharfan-Dabaja MA; Kim J; Yue B; Dalia S; Pinilla-Ibarz J; Anasetti C; Locke FL
Leuk Res; 2014 Oct; 38(10):1165-72. PubMed ID: 24889511
[TBL] [Abstract][Full Text] [Related]
9. HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research.
Verneris MR; Lee SJ; Ahn KW; Wang HL; Battiwalla M; Inamoto Y; Fernandez-Vina MA; Gajewski J; Pidala J; Munker R; Aljurf M; Saber W; Spellman S; Koreth J
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1783-9. PubMed ID: 26055300
[TBL] [Abstract][Full Text] [Related]
10. Donor-Specific HLA Antibodies Are Associated with Graft Failure and Delayed Hematologic Recovery after Unrelated Donor Hematopoietic Cell Transplantation.
Lima ACM; Getz J; do Amaral GB; Loth G; Funke VAM; Nabhan SK; Petterle RR; de Marco R; Gerbase-DeLima M; Pereira NF; Bonfim C; Pasquini R
Transplant Cell Ther; 2023 Aug; 29(8):493.e1-493.e10. PubMed ID: 37220839
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.
van Gelder M; de Wreede LC; Bornhäuser M; Niederwieser D; Karas M; Anderson NS; Gramatzki M; Dreger P; Michallet M; Petersen E; Bunjes D; Potter M; Beelen D; Cornelissen JJ; Yakoub-Agha I; Russell NH; Finke J; Schoemans H; Vitek A; Urbano-Ispízua Á; Blaise D; Volin L; Chevallier P; Caballero D; Putter H; van Biezen A; Henseler A; Schönland S; Kröger N; Schetelig J
Bone Marrow Transplant; 2017 Mar; 52(3):372-380. PubMed ID: 27941763
[TBL] [Abstract][Full Text] [Related]
12. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).
Efebera YA; Geyer S; Andritsos L; Vasu S; Jaglowski S; Bingman A; Blum W; Klisovic R; Hofmeister CC; Benson DM; Penza S; Elder P; Cortright K; Kitzler R; Coombes K; O'Donnell L; Daneault B; Bradbury H; Zhang J; Chen X; Garman S; Ranganathan P; Yu X; Hofstetter J; Yu J; Garzon R; Scrape SR; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Jan; 22(1):71-9. PubMed ID: 26256940
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT.
van Gorkom G; van Gelder M; Eikema DJ; Blok HJ; van Lint MT; Koc Y; Ciceri F; Beelen D; Chevallier P; Selleslag D; Blaise D; Foá R; Corradini P; Castagna L; Moreno C; Solano C; Müller LP; Tischer J; Hilgendorf I; Hallek M; Bittenbring J; Theobald M; Schetelig J; Kröger N; ;
Bone Marrow Transplant; 2018 Mar; 53(3):255-263. PubMed ID: 29255169
[TBL] [Abstract][Full Text] [Related]
15. Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.
Nath K; Lee J; Elko TA; Levy L; Preston E; Devlin SM; Ponce DM; Lin RJ; Shaffer BC; Cho C; Politikos I; Jakubowski AA; Park JH; Rampal R; Perales MA; Tallman MS; Barker JN; Berman E; Tamari R; Stein E; Giralt SA; Gyurkocza B
Am J Hematol; 2023 Dec; 98(12):1869-1876. PubMed ID: 37688521
[TBL] [Abstract][Full Text] [Related]
16. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies.
Voshtina E; Szabo A; Hamadani M; Fenske TS; D'Souza A; Chhabra S; Saber W; Drobyski WR; Hari P; Shah NN
Biol Blood Marrow Transplant; 2019 Jan; 25(1):e33-e38. PubMed ID: 30244105
[TBL] [Abstract][Full Text] [Related]
17. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
[TBL] [Abstract][Full Text] [Related]
18. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome.
Herrera AF; Ahn KW; Litovich C; Chen Y; Assal A; Bashir Q; Bayer RL; Coleman M; DeFilipp Z; Farhadfar N; Greenwood M; Hahn T; Horwitz M; Jacobson C; Jaglowski S; Lachance S; Langston A; Mattar B; Maziarz RT; McGuirk J; Mian MAH; Nathan S; Phillips A; Rakszawski K; Sengeloev H; Shenoy S; Stuart R; Sauter CS; Kharfan-Dabaja MA; Hamadani M
Blood Adv; 2021 Sep; 5(18):3528-3539. PubMed ID: 34496026
[TBL] [Abstract][Full Text] [Related]
19. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
